News and Trends 15 Nov 2022 Researchers create mini ‘bone marrow in a dish’ to boost anti-cancer treatments Scientists from Oxford University and the University of Birmingham in the U.K. have made the first bone marrow ‘organoids’ that capture the key features of human bone marrow. The technology, which is the subject of a patent application filed by University of Birmingham Enterprise, will allow for the screening of multiple anti-cancer drugs at the […] November 15, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 15 Nov 2022 Bel Group and Standing Ovation partner on cheese proteins Dairy giant Bel Group and start-up Standing Ovation are partnering on incorporating casein milk protein into Bel’s alternative cheese offerings. In September, Bel acquired an equity stake in Standing Ovation. Standing Ovation has developed a precision fermentation process that produces caseins of non-animal origin. These proteins are identical to those present in milk. Standing Ovation’s […] November 15, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 15 Nov 2022 Potential new lead compounds for treatment of depression and anxiety disorders Currently, various classes of drugs are available for the treatment of mental illnesses – such as depression and anxiety disorders. However, although these drugs have benefits, they can also be associated with adverse side-effects. A research group has conducted a study to identify new drugs that could potentially be used for the treatment of neuropsychiatric […] November 15, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 15 Nov 2022 Researchers awarded £2M to develop drugs to prevent epileptic seizures in children Scientists at Aston University in the U.K. have started work on a project that will look for new drug treatments to prevent the onset of childhood epilepsy. The three-year Medical Research Council (MRC) funded project is a collaboration led by researchers in the College of Health and Life Sciences at Aston University, partnered with Bristol […] November 15, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 15 Nov 2022 Avanzanite Bioscience looks to commercialize innovative medicines for rare diseases in Europe Avanzanite Bioscience B.V. has officially launched its commercial-stage enterprise, to expand patient access to medicines for rare diseases in Europe while unlocking revenue and growth potential for emerging research-based biopharmaceutical originators. Avanzanite, a fully authorized distributor of medicinal products, partners with biopharmaceutical collaborators through flexible, bespoke licensing and distribution partnerships across Europe. The company’s business […] November 15, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 15 Nov 2022 First patient dosed in Nouscom colorectal cancer study Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized immunotherapies, says the first patient has been dosed in a randomized phase 2 clinical trial evaluating NOUS-209 in combination with anti-PD1 checkpoint inhibitor (CPI) pembrolizumab versus pembrolizumab alone. NOUS-209 is an off-the-shelf immunotherapy targeting 209 specific neoantigens for the treatment of mismatch repair/microsatellite instable high […] November 15, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 15 Nov 2022 Beckley Psytech completes treatment resistant depression and alcohol use disorder study Beckley Psytech, a private, clinical-stage biotechnology company dedicated to addressing neuropsychiatric conditions through the novel application of psychedelic medicines, has completed its phase I clinical study of BPL-003, a synthetic intranasal formulation of 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT), which is under development for treatment resistant depression and alcohol use disorder. The double-blind, randomized, single ascending dose study […] November 15, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 15 Nov 2022 Biotheus enters agreement with Hansoh Pharma for bispecific antibody Biotheus Inc., a clinical-stage biotech company focused on the discovery and development of biologics for oncology and inflammatory diseases, has entered into a collaboration agreement with Hansoh Pharmaceuticals, for Biotheus’ EGFR/MET bispecific antibody (also known as PM1080) in China, Hong Kong, Macao and Taiwan. Under the terms of the agreement, Hansoh will be granted by […] November 15, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 15 Nov 2022 BrainEver and 3P Biopharmaceuticals developing drug with hopes to cure ALS 3P BioPharmaceuticals and BrainEver are to collaborate on developing hEng1, a recombinant homeoprotein, to treat pathologies such as amyotrophic lateral sclerosis (ALS) or Parkinson’s disease. 3P BioPharmaceuticals is a contract development and manufacturing organization (CDMO) specializing in the process development and cGMP manufacturing of biological products, and BrainEver is a French biotechnology company focusing on […] November 15, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 14 Nov 2022 Nuance Pharma’s RSV vaccine cleared for trial in China Nuance Pharma says China’s Center for Drug Evaluation (CDE) has approved its investigational new drug (IND) application supporting its pivotal phase III clinical trial of MVA-BN RSV vaccine against respiratory syncytial virus (RSV) in adults in China. MVA-BN RSV is being developed for the prevention of RSV in older adults. The vaccine incorporates five distinct RSV […] November 14, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 14 Nov 2022 HUTCHMED announces positive gastric cancer study results in China HUTCHMED (China) Limited has announced initial results from FRUTIGA, a phase III study of fruquintinib combined with paclitaxel in 703 Chinese patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. The trial was positive, having met one of the primary endpoints of statistically significant improvement in progression-free survival (PFS), which is clinically meaningful. The other […] November 14, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 14 Nov 2022 Nutcracker Therapeutics sees anti-tumor responses of lead mRNA immunotherapy Nutcracker Therapeutics, Inc. has presented the first set of preclinical data for its lead oncology mRNA therapeutic, NTX-250, at the 37th annual Society for Immunotherapy of Cancer meeting. The company said the data demonstrate that NTX-250 has the ability to elicit strong anti-tumor responses in C3.43 murine tumor models and induce an immune response in […] November 14, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email